Neogen Corporation Finite-Lived Intangible Asset, Expected Amortization, Year One
Neogen Corporation (NEOG) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $93.90 million as of 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-07-30
- 2026-05-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $93.90M.
- 2025-05-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $96.00M.
- 2024-05-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $96.00M.
- 2024-02-29: Finite-Lived Intangible Asset, Expected Amortization, Year One $95.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One | Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed |
|---|---|---|
| 2026-05-31 | $93.90M 10-K · filed 2026-07-30 | |
| 2025-05-31 | $96.00M 10-K · filed 2025-07-30 | |
| 2024-05-31 | $96.00M 10-K · filed 2024-07-30 | |
| 2024-02-29 | $95.00M 10-Q · filed 2024-04-09 | |
| 2023-11-30 | $95.00M 10-Q · filed 2024-01-09 | |
| 2023-08-31 | $95.00M 10-Q · filed 2023-10-10 | |
| 2023-02-28 | $91.80M 10-Q · filed 2023-04-04 | |
| 2022-11-30 | $90.80M 10-Q · filed 2023-01-09 | |
| 2022-05-31 | $93.20M 10-K · filed 2023-08-15 | $9.63M 10-K · filed 2022-07-27 |
| 2021-05-31 | $8.33M 10-K · filed 2021-07-30 | |
| 2020-05-31 | $6.57M 10-K · filed 2020-07-30 | |
| 2019-05-31 | $6.66M 10-K · filed 2019-07-30 | |
| 2018-05-31 | $6.18M 10-K · filed 2018-07-27 | |
| 2017-05-31 | $5.95M 10-K · filed 2017-07-28 | |
| 2016-05-31 | $5.76M 10-K · filed 2016-07-29 | |
| 2015-05-31 | $4.32M 10-K · filed 2015-07-30 | |
| 2014-05-31 | $4.16M 10-K · filed 2014-07-30 | |
| 2013-05-31 | $3.07M 10-K · filed 2013-07-30 | |
| 2012-05-31 | $2.44M 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |